FDA approves Cimerli as the first and only interchangeable biosimilar to Lucentis for all five indications, with 12 months of interchangeability exclusivity.
Coherus BioSciences, Inc. announced that the FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all five indications, meeting the FDA’s rigorous standards to the reference product, including safety, efficacy and quality. Cimerli belongs to the anti-VEGF therapy class of biologics that has been revolutionary in helping retinal patients maintain or gain vision
Cimerli the only biosimilar product interchangeable with Lucentis across all five indications, will provide both greater treatment access and choice for patients, payors and providers in the U.S. retinal disease community,” said Paul Reider, Chief Commercial Officer of Coherus BioSciences. “Coherus is the only company in the $7 billion anti-VEGF ophthalmology market with a demonstrated track record of U.S. commercial biosimilar success. ”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.